

Efficacy of Tenofovir-Emtricitabine and Boosted Atazanavir Combination in the Treatment of HIV-Infected Patients Naïve to Antiretroviral Therapy

ACTHIV
 May 31 – June 3,
 2007
 Dallas, Texas

Homayoon Khanlou, Paul DenOuden, Catherine Chien, Alen Voskanian,
 Parveen Kaur, Marjan Javanbakht, Charles Farthing
 AIDS Healthcare Foundation, Los Angeles, CA, United States

Introduction:

- Clinical information is lacking regarding the efficacy of tenofovir (TDF) and emtricitabine (FTC) in combination with boosted atazanavir (ATV/r) in the treatment of antiretroviral naïve patients.


Methods :

- Using our electronic medical records, we undertook a retrospective analysis of all patients naïve to antiretroviral therapy who started treatment with ATV/r+TDF+FTC and compared them to those who started with TDF+FTC and a non-nucleoside reverse transcriptase inhibitor (NNRTI): either efavirenz or nevirapine. Patients were included if they had an adherence score of >95% (as assessed by patients and providers) and had at least 12 months of follow-up.
- The HIV-1 RNA levels and CD4 counts were compared at baseline and at 6 and 12 months.


Results:

- We identified 107 patients who fit study criteria.
- Median age of pts was 38 [24-68] years.
- 94% were male, 6% were female.
- Ethnicity/Race: Hispanic (45%), White (36%), Black (11%), Asian (6%) and Native-American (2%)
- Treatment arms:
 - TDF+FTC+ATV/r: n=44
 - TDF+FTC+EFV: n=48 TDF+FTC+NVP: n=15
- The baseline median HIV-1 RNA and CD4 counts were 4.96 log₁₀ and 213 cells/mm³ (1-500) in the ATV/r group compared to 4.86 log₁₀ and 239 cells/mm³ (3-945) in the NNRTI group.

Baseline and Follow-up HIV-RNA



Baseline and Follow-up CD4



Percentage of Patients Achieving HIV-RNA <50 copies/mL:

	Week 24	Week 48
TDF+FTC+ATV/r	52%	68%
TDF+FTC+NNRTI	62%	79%
p-value	0.32	0.19

p-value obtained by using Mantel-Haenszel Chi-square Method

Corresponding Author:
Homayoon Khanlou, MD
 AIDS Healthcare Foundation
 4835 Van Nuys Blvd, suite 200
 Sherman Oaks, CA 91403
 Tel: (818) 380-2626
 Fax: (818) 380-2620
 E-mail: homayoon.khanlou@
 aidshealth.org

Conclusions:

- Results from this clinical cohort revealed equivalent rates of immunologic and antiviral efficacy for the two treatment groups. There was a trend, however, toward a greater proportion of patients in the NNRTI-based treatment group achieving HIV-1 viral load <50 copies/mL at 12 months. Larger studies are warranted.